article thumbnail

Phase 1 Clinical Trial Data Indicate IGC’s THC-based Investigational New Drug May Reduce Symptoms of Dementia in Alzheimer’s Patients

Cannabis Law Report

(IGC) is excited to present preliminary positive secondary end point findings from its Phase 1 clinical trial for IGC-AD1. The investigational new drug, IGC-AD1, is IGC’s proprietary Tetrahydrocannabinol (THC)-based candidate designed to treat certain symptoms of Alzheimer’s disease. The degree of the decrease varied by cohort.

article thumbnail

CBG ‘very helpful’ when treating medical conditions, first survey of its kind finds

The Cannigma

No clinical trial was used in the compilation of the study. The researchers themselves wrote that the study is the first “to document self-reported efficacy of CBG-predominant products,” and provides further indication that “CBG-predominant cannabis-based medicines should be studied in randomized controlled trials.”.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

MMJ Laws In Texas: Your Complete Guide

MMJ Recs

Enacted in 2015, the program was designed to provide a narrow avenue for patients suffering from qualifying conditions to access low-THC cannabis under the supervision of qualified healthcare professionals. THC is the psychoactive compound responsible for the “high” associated with marijuana use.

Law 52
article thumbnail

Can Marijuana Reverse Bone Loss?

CannaMD

In recent years, research has revealed that two of marijuana’s two major cannabinoids — THC and CBD — can interact with the human endocannabinoid system to influence bone healing and regeneration. THC, CBD & THE ECS. CBD PROMOTES BONE GROWTH. In their summary, the study’s authors noted that.

Marijuana 111
article thumbnail

CBD: Exploring The Therapeutic Effects of Cannabis Without the High

Canna Care Docs

CBD is one of close to 85 cannabinoids present in cannabis, with THC being the most commonly known. With increased attention and further legalization efforts in the United States, research surrounding the health applications are still in its infancy stages, but documentation and clinical trials continue to flow into the public sphere.

article thumbnail

Recent Study Suggests MMJ Cards Increase the Risk of CUD—But Is There More to It?

Veriheal

Clinical Trial Sample Size. The trial was conducted with just 186 participants, which is far too small of a sample size to provide findings generalizable to the larger population. a necessary question to address as medical marijuana becomes more accessible. Various Limitations.

article thumbnail

CBD Science Update

Project CBD

Harvard University scientist Staci Gruber shared encouraging results from “the first open-label to double-blind clinical trial” assessing the impact of a high- CBD , low- THC sublingual tincture in patients who experience moderate anxiety. Twenty percent of the samples contained less CBD than indicated on the label.

CBD 218